Downloads: 82

Files in This Item:
File Description SizeFormat 
jdi.12858.pdf383.14 kBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorUsui, Ryota
dc.contributor.authorSakuramachi, Yui
dc.contributor.authorSeino, Yusuke
dc.contributor.authorMurotani, Kenta
dc.contributor.authorKuwata, Hitoshi
dc.contributor.authorTatsuoka, Hisato
dc.contributor.authorHamamoto, Yoshiyuki
dc.contributor.authorKurose, Takeshi
dc.contributor.authorSeino, Yutaka
dc.contributor.authorYabe, Daisuke
dc.contributor.alternative矢部, 大介
dc.date.accessioned2019-03-04T01:15:20Z-
dc.date.available2019-03-04T01:15:20Z-
dc.date.issued2018-07
dc.identifier.issn2040-1116
dc.identifier.urihttp://hdl.handle.net/2433/236656-
dc.description.abstractWe have reported that the HbA1c‐lowering effects of liraglutide/basal insulin combination rely on remaining β‐cell function and that the cut‐off value of the C‐peptide immunoreactivity index (CPI), a β‐cell function‐related index frequently used in Japanese clinical settings, is 1.103 for the achievement of HbA1c <7.0% at 54 weeks after initiating the liraglutide/basal insulin combination. Wilbrink et al claimed that glucose‐lowering effects of glucagon‐like peptide‐1 receptor agonist liraglutide depend of duration of type 2 diabetes; while our resent study published in the Journal of Diabetes Investigation failed to detect such dependency. This discrepancy might be due to several reasons including co‐administration of basal insulin with liraglutide in our study; ethnic difference in T2D pathophysiology between the two study; and difference in sample size (The Usui study on liraglutide/basal insulin, n = 38; the Usui study on liraglutide monotherapy or SU combination, n=88; and the Wilbrink study, n = 69).
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherWiley
dc.rights© 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
dc.titleReply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after init
dc.type.niitypeJournal Article
dc.identifier.jtitleJournal of Diabetes Investigation
dc.identifier.volume9
dc.identifier.issue4
dc.identifier.spage981
dc.identifier.epage983
dc.relation.doi10.1111/jdi.12858
dc.textversionpublisher
dc.addressCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital
dc.addressCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital・Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute
dc.addressDepartment of Endocrinology and Diabetes Metabolic Medicine, Nagoya University Graduate School of Medicine
dc.addressDivision of Biostatistics, Clinical Research Center, Aichi Medical University Hospital
dc.addressCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital・Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute
dc.addressCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital・Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute
dc.addressCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital・Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute・Center for Metabolism and Clinical Nutrition, Kansai Electric Power Hospital
dc.addressCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital・Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute
dc.addressCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital・Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute
dc.addressCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital・Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute・Division of Molecular and Metabolic Medicine, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine・Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine
dc.identifier.pmid29974670
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.